Source comparison
CJC-1295 No DAC vs Modified Analog: Bioavailability Comparison
Plasma Half-Life ~30 minutes 6–8 days No DAC variants require precise timing; DAC version allows flexible dosing Peak Plasma Concentration 20–30 minutes post-injection 48–72 hours post-injection 15–25 minutes post-injection Rapid-acting analogs produce sharper
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- 6–8 days
- No DAC variants require precise timing; DAC version allows flexible dosing
- Peak Plasma Concentration
- 20–30 minutes post-injection
- 48–72 hours post-injection
- 15–25 minutes post-injection
- Rapid-acting analogs produce sharper GH pulses but require more frequent administration
- Subcutaneous Bioavailability
- 65–85% (site-dependent)
- 90–95% (albumin binding extends residence)
- 60–75% (higher DPP-4 susceptibility)
- DAC modification significantly improves absorption efficiency through reduced enzymatic clearance
- Injection Frequency
- Daily or multiple daily
- Once weekly
- 2–3× daily
- No DAC protocols demand stricter adherence; missed doses lose therapeutic window entirely
- GH Pulse Pattern
- Single pronounced pulse
- Sustained elevated baseline
- Pulsatile mimicking natural secretion
- Pulsatile patterns (No DAC, Modified GRF) may better preserve receptor sensitivity vs continuous elevation
- DPP-4 Resistance
- High (4 amino acid substitutions)
- High + albumin protection
- Moderate (prone to N-terminal cleavage)
- CJC-1295 variants (with or without DAC) demonstrate superior enzymatic stability vs unmodified analogs